CureVac B.V

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG

The shares of CureVac BV (NASDAQ:CVAC) are soaring this morning, up 18.5% at $102.88 at last check.

CVAC Soars on Bayer COVID-19 Vaccine Collaboration

LOS ANGELES--(BUSINESS WIRE)---- $CVAC #COVID19--Investor's Business Daily (IBD), a leading financial news and research organization, today announced its list of the 100 Best Companies of 2020. Companies were selected based on stock performance throughout a year heavily influenced by the COVID-19 pandemic. Tesla claimed the top spot, as tech companies excelled, while a full quarter of the 100 Best Companies were biotechs. Despite the unstable environment, approximately one-third of the 100 Best Companies went pub

IBD Announces 100 Best Companies of 2020

The German biotech struck a deal with chemicals-and-drugs giant Bayer to accelerate the development and supply of its Covid-19 vaccine candidate.

CureVac Forms Covid-19 Vaccine Alliance With Bayer. The Stock Is Surging.

Companies enter into a collaboration and services agreement Bayer to support CureVac in numerous areas, including development and supply of CVnCoV CureVac benefits from Bayer's expertise and established infrastructure Plan to facilitate the supply of several hundred million doses BERLIN and TUBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / January 7, 2021 / Bayer has signed a collaboration and services agreement with CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA).

CureVac : CureVac and Bayer Join Forces on COVID-19 Vaccine Candidate CVnCoV

German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, the two companies said on Thursday.

CureVac strikes COVID-19 vaccine alliance deal with Bayer

German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, daily Bild reported.

CureVac strikes COVID-19 vaccine alliance deal with Bayer -Bild

Study to assess safety and immunogenicity of CVnCoV in high-risk population group Study builds on observational epidemiological study TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / December 21, 2020 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced today that the first participant in a clinical Phase 3 study with its COVID-19 vaccine, CVnCoV, in healthcare workers at the University Medical Center Mainz will be vaccinated on December 22, 2020.

CureVac and the University Medical Center Mainz Start Phase 3 Clinical Trial for COVID-19 Vaccine Candidate, CVnCoV, in Healthcare Workers

Arcturus Therapeutics

Novavax

Vaxart

Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.

4 Small COVID-19 Vaccine Makers to Look Out for in 2021

CureVac (CVAC) doses the first patient in a pivotal study on its COVID-19 vaccine candidate, CVnCoV. Shares rise following this development.

CureVac (CVAC) Begins Pivotal Study on COVID-19 Vaccine

CureVac N.V. (NASDAQ: CVAC) advanced in the fight against COVID-19 by beginning enrollment in its midstage vaccine candidate study.

How CureVac Is Advancing in the Fight Against COVID-19

Tübingen-based CureVac said the Phase 3 trial will include more than 35,000 volunteers in Europe and Latin America

CureVac starts Phase 3 clinical trial of its Covid-19 vaccine candidate

If we judge by return on investment, these two mid-cap biotechs may be the ultimate winners of the coronavirus vaccine race.

2 Surprising Coronavirus Vaccine Stocks to Buy Right Now

AstraZeneca

BioNTech SE

Johnson & Johnson

Moderna

Pfizer

Here's what you need to know about all of the leaders in the coronavirus vaccine race.

COVID Vaccine Stocks Update: Where Things Stand Now

And it's not too far behind coronavirus vaccine leaders Pfizer and Moderna.

This Under-the-Radar COVID Vaccine Stock Has a Tesla Tie-In

The European Union could pay more than $10 billion to secure hundreds of millions of doses of the vaccine candidates being developed by Pfizer-BioNTech and CureVac, an EU official involved in the talks told Reuters.

Exclusive: EU could pay over $10 billion for Pfizer and CureVac vaccines - source

CureVac expects to announce partnerships with vaccine developers and manufacturers in coming weeks to ramp up capacity of its potential vaccine candidate.

German vaccine maker CureVac ramps up capacity to 300 million COVID-19 doses in 2021

Telesis Bio Inc

Great efficacy results for mRNA COVID-19 vaccines so far could bode well for these three stocks.

3 mRNA Coronavirus Vaccine Stocks to Check Out That Aren't Pfizer, BioNTech, or Moderna

Tesla

Biotech is on every investor's mind as we move closer and closer to a successful vaccine for the coronavirus. Here are three contenders for your portfolio.

3 Best Biotech Stocks to Buy Right Now

German biopharma CureVac BV (NASDAQ: CVAC) — which is developing an  mRNA vaccine against the novel coronavirus — was rallying Tuesday following the release of detailed interim Phase 1 data for the investigational vaccine. What Happened: Interim analysis of data from the dose-escalation Phase 1 study in healthy volunteers showed that two doses of the vaccine candidate CVnCoV, ranging from 2 μg to 12 μg per dose and administered 28 days apart, were safe, according to a preprint available on medRxiv.

CureVac Rallies On Interim Phase 1 Data For COVID-19 Vaccine Candidate: What You Need To Know

Shares of CureVac gained 8.0% in premarket trading on Tuesday after the company disclosed additional clinical data about how its COVID-19 vaccine candidate is performing in a Phase 1 clinical trial. Interim data from an early-stage clinical trial was published Tuesday as a preprint, according to the U.S.-listed German company, which is running clinical trials for its experimental RNA vaccine in Belgium and Germany.

CureVac's stock is up 8% as it shares additional Phase 1 data about its COVID-19 vaccine candidate

Participants in the phase 1 clinical trial mounted an immune response after being inoculated with CVnCoV.

CureVac Reports Early-Stage Data for Its Coronavirus Vaccine Candidate

Recent hot IPO CureVac reported positive Phase 1 clinical trials data for its Covid-19 vaccine candidate, which is among a number based on mRNA technology. CVAC stock rose on the news.

CureVac Posts Positive Early Data For Its Covid-19 Vaccine Candidate

German biotech CureVac said advanced clinical trials are on track to launch by the end of 2020.

CureVac's COVID-19 vaccine shows immune response in Phase 1 trial

Inovio Pharmaceuticals

The World Health Organization is managing a global vaccine program without U.S. participation, and it could have a big impact for investors.

Investors Betting on a Coronavirus Vaccine Better Know Who Gets First Dibs in Global Pact

CureVac is using the same messenger RNA approach that Moderna uses. Why is Moderna getting all the headlines?

News for CureVac B.V Stock (CVAC)